Biomarkers in Patients With Advanced Rhabdomyosarcoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01668095
First received: August 15, 2012
Last updated: August 18, 2012
Last verified: August 2012
  Purpose

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial studies tumor tissue from patients with rhabdomyosarcoma to identify important proteins and biomarkers.


Condition Intervention
Sarcoma
Genetic: microarray analysis
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

Study Type: Observational
Official Title: Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: August 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To investigate whether the expression of a subset of proteins (by immunohistochemistry), known to be involved in the Pax3, Pax7, and Patched-1 neuromuscular development pathways, are dysregulated in advanced and relapsed alveolar and embryonal rhabdomyosarcomas.

OUTLINE: Iimmunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • 8 tissue microarrays (TMA) slides of the following diseases available:

    • Alveolar rhabdomyosarcoma
    • Embryonal rhabdomyosarcoma
    • Anaplastic rhabdomyosarcoma

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01668095

Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Charles Keller, MD Oregon Health and Science University
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01668095     History of Changes
Other Study ID Numbers: CDR0000738499, COG-ARST12B8
Study First Received: August 15, 2012
Last Updated: August 18, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
adult rhabdomyosarcoma
alveolar childhood rhabdomyosarcoma
embryonal childhood rhabdomyosarcoma
previously treated childhood rhabdomyosarcoma
recurrent adult soft tissue sarcoma
recurrent childhood rhabdomyosarcoma
stage III adult soft tissue sarcoma
stage IV adult soft tissue sarcoma

Additional relevant MeSH terms:
Rhabdomyosarcoma
Sarcoma
Myosarcoma
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on April 17, 2014